Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumors
Robert Svensson(Malmö University), Peter J. Tummino(Intarcia Therapeutics (United States)), Hye-Sun Oh(Ensemble Therapeutics (United States)), Scott Boiko(Ensemble Therapeutics (United States)), Angela V. Toms, Anita Scheuber(Nimbus (Italy)), Justin A. Caravella(Rockefeller University Press), Samantha Carreiro(Ensemble Therapeutics (United States)), Silvana Leit, Zhenhong Li(Ensemble Therapeutics (United States)), Derun Li(Ensemble Therapeutics (United States)), Yuet Mei Khong(Ensemble Therapeutics (United States)), Avinash Phadke(Achillion Pharmaceuticals (United States)), Suzanne Jacques-O’Hagan(Ensemble Therapeutics (United States)), Beth Browning(Ensemble Therapeutics (United States)), Emily Florine(Ensemble Therapeutics (United States))
Cited by 5
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550